Worth reading
83Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
310830300
¥Wording
Conditional
How definitive the wording is.Details of issuance or disposal
Issuance of new shares by third-party allotment
Who receives how much3,139,700Shares
3,139,700 common shares
Cyntec Co., Ltd.3,139,700 shares
The lower thin line represents the existing number of shares to which these shares will be added.
¥99 per share
Total issue value
¥310,830,300
Amount of funds to be raised
Total payment amount of ¥310,830,300, less estimated net proceeds of ¥300,830,300
Estimated issuance expenses
¥10,000,000
Specific use of funds
Investment funds for new businesses and investment projects in the life sciences fieldAmount ¥300.830 million / Scheduled timing of expenditures October 2026 to September 2028
Existing Shares and Increase
+3.82%Rate of increase
82,100,758 shares85,240,458Shares
3.82% (3.83% on a voting rights basis)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Offering structure
Major shareholders after the offering
Name Cyntec Co., Ltd. / Shareholding ratio 3.68％Name セントラル短資株式会社 / Shareholding ratio 1.92％Name 株式会社ＳＢＩ証券 / Shareholding ratio 1.88％Name MATSUI SECURITIES CO.,LTD. / Shareholding ratio 1.31％Name 上田八木短資株式会社 / Shareholding ratio 1.29％Name Nakatomi Ichiro (中冨 一郎) / Shareholding ratio 1.18％Name 楽天証券株式会社 / Shareholding ratio 1.11％Name Noritsu Koki Co.,Ltd. / Shareholding ratio 0.88％Name Monex Securities, Inc. / Shareholding ratio 0.79％Name 京滋建設株式会社 / Shareholding ratio 0.75％
Intended allottee's holding policy
The allottee intends to hold the Company’s shares acquired through this third-party allotment on a long-term basis. The Company plans to obtain a written undertaking confirming that if all or part of the shares are transferred within 2 years of payment, the details of the transfer will be reported to the Company in writing, among other matters.
Payment date
30 October 2026 to 30 December 2026
Basis for determining the amount to be paid
The closing price on the trading day immediately preceding the Board of Directors’ resolution, 16 September 2026, was ¥99. This represents a 3.88% discount to the ¥103 average over the preceding 1 month, a 1.98% discount to the ¥101 average over the preceding 3 months, and a 16.10% discount to the ¥118 average over the preceding 6 months.
Procedures under the Corporate Code of Conduct
As the dilution rate is below 25% and the transaction does not involve a change in the controlling shareholder, it is not necessary to obtain an opinion from an independent third party or conduct procedures to confirm shareholder intent.
Most recent equity financing
Timing Allotted on 30 October 2025 / Type Issuance of Series 22 stock acquisition rights through a third-party allotment with an exercise price adjustment provision / Amount ¥6,368,350,000 in expected proceeds (estimated net proceeds)
Impact on Business Performance
The specific impact on results for the fiscal year ending March 2027 is expected to be minor.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of new shares by third-party allotment |
| Number of shares to be issued or disposed of | 3,139,700 common shares |
| Issue price and disposal price | ¥99 per share |
| Total issue value | ¥310,830,300 |
| Amount of funds to be raised | Total payment amount of ¥310,830,300, less estimated net proceeds of ¥300,830,300 |
| Estimated issuance expenses | ¥10,000,000 |
| Specific use of funds | Details Investment funds for new businesses and investment projects in the life sciences field / Amount ¥300.830 million / Scheduled timing of expenditures October 2026 to September 2028 |
| Payment date | 30 October 2026 to 30 December 2026 |
| Intended allottee | Name Cyntec Co., Ltd. / Number of Shares 3,139,700 shares |
| Intended allottee's holding policy | The allottee intends to hold the Company’s shares acquired through this third-party allotment on a long-term basis. The Company plans to obtain a written undertaking confirming that if all or part of the shares are transferred within 2 years of payment, the details of the transfer will be reported to the Company in writing, among other matters. |
| Dilution Rate | 3.82% (3.83% on a voting rights basis) |
| Total number of issued shares | 82,100,758 shares → 85,240,458 shares（3.82％） |
| Basis for determining the amount to be paid | The closing price on the trading day immediately preceding the Board of Directors’ resolution, 16 September 2026, was ¥99. This represents a 3.88% discount to the ¥103 average over the preceding 1 month, a 1.98% discount to the ¥101 average over the preceding 3 months, and a 16.10% discount to the ¥118 average over the preceding 6 months. |
| Procedures under the Corporate Code of Conduct | As the dilution rate is below 25% and the transaction does not involve a change in the controlling shareholder, it is not necessary to obtain an opinion from an independent third party or conduct procedures to confirm shareholder intent. |
| Most recent equity financing | Timing Allotted on 30 October 2025 / Type Issuance of Series 22 stock acquisition rights through a third-party allotment with an exercise price adjustment provision / Amount ¥6,368,350,000 in expected proceeds (estimated net proceeds) |
| Major shareholders after the offering | Name Cyntec Co., Ltd. / Shareholding ratio 3.68％, Name セントラル短資株式会社 / Shareholding ratio 1.92％, Name 株式会社ＳＢＩ証券 / Shareholding ratio 1.88％, Name MATSUI SECURITIES CO.,LTD. / Shareholding ratio 1.31％, Name 上田八木短資株式会社 / Shareholding ratio 1.29％, Name Nakatomi Ichiro (中冨 一郎) / Shareholding ratio 1.18％, Name 楽天証券株式会社 / Shareholding ratio 1.11％, Name Noritsu Koki Co.,Ltd. / Shareholding ratio 0.88％, Name Monex Securities, Inc. / Shareholding ratio 0.79％, Name 京滋建設株式会社 / Shareholding ratio 0.75％ |
| Impact on Business Performance | The specific impact on results for the fiscal year ending March 2027 is expected to be minor. |
Items this document does not state (11)
Exercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split Ratio
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To promote a strategic capital and business alliance with OEP, establish a long-term capital relationship, and secure funds for investment in new businesses and investment projects in the life sciences field.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.